ArticleJournal of comparative effectiveness research2025

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Whitney S Graybill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.